Biogen May Be a Target For Acquisition at Around $42 Billion Valuation
<p>Analysts at Oppenheimer provided their views on <a href='https://financialmodelingprep.com/financial-summary/BIIB'>Biogen Inc. (NASDAQ:BIIB) </a>stating that the company appears to be in play as a potential acquisition target based on Thursday news mentioning the possibility of the company to be taken out in a deal valued at  around $42 billion. </p>
<p>While the analysts take no view on the likelihood of an alleged deal, it would represent only around 20% premium over the 30- day average price, which would be relatively low compared to other deals. Biotech acquisition premiums have steadily increased since a relative low point in 2017.</p>
NASDAQ:BIIB